Table 2.
Crude incidence and multivariable associations of death and cardiac events by NT-proBNP status among exposed survivors with normal LVEF (≥53%) at baseline
| No of Events/Total No at Risk | NT-proBNP Status | Adjusted Hazard Ratio for Abnormal NT-proBNP | ||||
|---|---|---|---|---|---|---|
| Abnormal | Normal | |||||
| Rate/1000 person-years (95% CI) | p-value | HR | 95% CI | |||
| Cardiac Mortality | 4/535 | 2.93 (2.81–3.07) | 0.96 (0.92–1.00) | <0.0001 | 3.31 | 0.32–34.59 |
| 1st Major Adverse Cardiac Event | 70/535 | 35.76 (35.28–36.23) | 24.56 (24.34–24.78) | <0.0001 | 1.75 | 1.04–2.94 |
| Myocardial Infarction | 11/535 | 1.48 (1.38–1.57) | 4.86 (4.77–4.96) | <0.0001 | 0.41 | 0.05–3.40 |
| Cardiomyopathy | 52/535 | 32.10 (31.66–32.55) | 15.98 (15.81–16.16) | <0.0001 | 2.28 | 1.28–4.08 |
| Vascular Disease | 8/535 | 1.47 (1.39–1.57) | 3.38 (3.30–3.46) | <0.0001 | 0.59 | 0.07–5.19 |
| Stroke | 3/535 | 1.47 (1.39–1.57) | 0.96 (0.92–1.00 | <0.0001 | 1.38 | 0.11–17.88 |
HR, hazard ratio; CI, confidence interval
Major Adverse Cardiac Event included myocardial infarction, cardiomyopathy, stroke or other vascular disease (excluding stroke and myocardial infarction) as defined in CTCAE grading from Table S2.
Analyses were limited to survivors exposed to cardiotoxic therapy with no history of grade 3–4 cardiomyopathy and normal LVEF at baseline assessment. Cardiac events are CTCAE grade 2–4.
P-value is comparing the rate of cardiac event by NT-proBNP status.
HR was adjusted for demographic variables of age at diagnosis, age at evaluation, sex, race/ethnicity (non-Hispanic white vs other), BMI and presence/absence of baseline cardiovascular risk factors (hypertension, diabetes, dyslipidemia).